QSI — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-11-05

• In August 2026, we announced that we committed to an organizational restructuring to align resources and spending with the updated Proteus development program launch timing, while maintaining resources for critical development, manufacturing and commercial readiness activities. As a result, we termi…

• Results of Operations for the Three and Nine Months Ended September 30, 2026 as Compared to the Three and Nine Months Ended September 30, 2025

• The following table presents the Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2026 and 2025 (dollars in thousands):

• Three months ended September 30,Nine months ended September 30,

• Three months ended September 30,Nine months ended September 30,

Text removed vs the prior filing · source: 10-Q · 2026-08-13

• Results of Operations for the Three and Six Months Ended June 30, 2026 as Compared to the Three and Six Months Ended June 30, 2025

• The following table presents the Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2026 and 2025 (dollars in thousands):

• Total revenue for the sale of our Platinum line of instruments, related reagent kits and service maintenance contracts decreased by $0.2 million, or 41.8%, and $0.8 million, or 58.0%, for the three and six months ended June 30, 2026, respectively, when compared to the same periods in 2025. The decre…

• Total cost of revenue decreased $0.1 million, or 28.3%, and $0.2 million, or 40.3%, for the three and six months ended June 30, 2026, when compared to the same periods in 2025. The change in the cost of revenue is directly correlated to the relative revenue and volume decreases for the three and six…

• Gross profit decreased $0.2 million, or 51.0%, and $0.6 million, or 70.6%, for the three and six months ended June 30, 2026, when compared to the same periods in 2025.

Text added vs the prior filing · source: 10-Q · 2026-11-05

• We are exposed to market risk with respect to certain of our cash and cash equivalents and marketable securities. As of September 30, 2026, our investments are comprised primarily of investments in money market funds backed by U.S. government issued securities, U.S. Treasury bills, U.S. government a…

Text removed vs the prior filing · source: 10-Q · 2026-08-13

• We are exposed to market risk with respect to certain of our cash and cash equivalents and marketable securities. As of June 30, 2026, our investments are comprised primarily of investments in money market funds backed by U.S. government

• issued securities, U.S. Treasury bills, U.S. government agency bonds, high-quality corporate bonds and commercial paper. The primary objective of our investments is the preservation of capital to fulfill liquidity needs. We do not enter into investments for trading or speculative purposes. Based on …

Text added vs the prior filing · source: 10-Q · 2026-11-05

• We rely on certain contract manufacturers to manufacture and supply our instruments, components of our instruments, and certain components of our consumable offerings. If these manufacturers should fail or not perform satisfactorily, or for economic or other reasons choose to end business with us, o…

• We rely on certain contract manufacturers to manufacture and supply our instruments, components of our instruments, and certain components of our consumable offerings. Since most of our contracts with these manufacturers do not commit them to carry inventory or make available any particular quantiti…

• In the event it becomes necessary to utilize different contract manufacturers for our products or components of our products, we would experience additional costs, delays and difficulties in doing so as a result of identifying and entering into an agreement with a new manufacturer as well as prepari…

• Certain of the components and consumables used in our instruments and consumable offerings are sourced from a limited number, or sole source suppliers. If we were to lose such a supplier, there can be no assurance that we will be able to identify or enter into an agreement with an alternative suppli…

• As the development and use of artificial intelligence (“AI”) has ramped up globally, overall supply chains have become constrained, potentially impacting our supply chain and ability to manufacture our products in a timely fashion to satisfy customer demand. Constraints in supply chains as a result …

Text added vs the prior filing · source: 10-Q · 2026-11-05

• Effective August 26, 2026, Dr. Jonathan Rothberg, who is a member of the Board, acting on his own behalf and on behalf of entities owned by trusts created for the benefit of his children, entered into a 10b5-1 sales plan (the “Sales Plan”) intended to satisfy the affirmative defense of Rule 10b5-1(c…

• Other than as disclosed above, during the quarter ended September 30, 2026, no other officers or directors, as defined in Rule 16a-1(f), adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Item 408 of Regulation S-K.

• On October 30, 2026, Quantum-Si Incorporated (the “Company”) entered into a Mutual Lease Termination and Settlement Agreement (the “Termination Agreement”) with Sterling City Science South Development, LLC (the “Landlord”). Under the Termination Agreement, the parties mutually terminated, effective …

• Under the Termination Agreement, the Landlord is required to pay the Company approximately $1.3 million. This consists of approximately $0.7 million in reimbursement of tenant improvement costs incurred by the Company, approximately $0.4 million as a refund, with interest, of the security deposit pa…

Text removed vs the prior filing · source: 10-Q · 2026-08-13

• During the quarter ended June 30, 2026, no officers or directors, as defined in Rule 16a-1(f), adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Item 408 of Regulation S-K.

• On August 10, 2026, the Company committed to an organizational restructuring program (the “2026 Restructuring Program”) designed to restructure resources focused specifically on its ProteusTM development program as well as other adjustments to streamline general and administrative expenses to align …

• In connection with the 2026 Restructuring Program, on August 10, 2026, the Company and John Vieceli, Ph.D., the Company’s Chief Product Officer, mutually agreed to end their employment relationship effective August 13, 2026 (the “Separation Date”). Dr. Vieceli is subject to the Amended and Restated …

• The material terms of Dr. Vieceli’s separation are described in, and the Severance Plan is filed as, Exhibit 10.18 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, which is incorporated by reference herein.